Xenon Pharmaceuticals Inc.
XENE
$55.23
-$2.67-4.61%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -60.25% | -44.76% | -46.24% | -35.71% | -46.81% |
| Total Depreciation and Amortization | -8.26% | -3.90% | -1.40% | 12.46% | 205.88% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 88.24% | -1.04% | 5.41% | 110.07% | -26.23% |
| Change in Net Operating Assets | 190.23% | 505.47% | -73.22% | -104.98% | 1,311.76% |
| Cash from Operations | -49.82% | -44.47% | -106.19% | -33.48% | -53.63% |
| Capital Expenditure | 59.39% | 52.37% | 89.63% | 77.13% | -903.85% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -36.53% | 3,467.28% | -25.55% | 180.35% | 141.42% |
| Cash from Investing | -36.35% | 7,637.15% | -24.66% | 179.90% | 141.08% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 836.00% | -- | -- | -- | -96.26% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 836.00% | -- | -- | -- | -96.26% |
| Foreign Exchange rate Adjustments | 91.01% | -111.11% | 412.87% | 82.56% | -570.33% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 71.80% | 37.15% | -75.94% | 70.97% | 12.27% |